Benign prostatic hyperplasia (BPH) Epidemiology Forecast, 2030

DelveInsight Business Research LLP

DelveInsight’s ‘Benign prostatic hyperplasia (BPH) – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Benign prostatic hyperplasia (BPH) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

The histologic Benign Prostatic Hyperplasia prevalence is approximately 10% for men in their 30s, 20% for men in their 40s, reaches 50% to 60% for men in their 60s, and is 80% to 90% for men in their 70s and 80s. Benign Prostatic Hyperplasia prevalence increases after the age of 40 years, with a prevalence of 8%–60% at age 90 years.

Scope of the Report

• The Benign prostatic hyperplasia (BPH) report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Benign prostatic hyperplasia (BPH) Epidemiology Report and Model provide an overview of the risk factors and global trends of Benign prostatic hyperplasia (BPH) in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight about the historical and forecasted patient pool of Benign prostatic hyperplasia (BPH) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Benign prostatic hyperplasia (BPH)
• The report provides the segmentation of the Benign prostatic hyperplasia (BPH) epidemiology

Request for sample pages: https://www.delveinsight.com/sample-request/benign-prostatic-hyperplasia-bph-epidemiology-forecast

Table of contents:

1. Key Insights 

2. Executive Summary of Benign prostatic hyperplasia (BPH)

3. Benign prostatic hyperplasia (BPH): Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Benign prostatic hyperplasia (BPH) Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Benign prostatic hyperplasia (BPH) Treatment and Management

6.2. Benign prostatic hyperplasia (BPH) Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

*The table of contents is not exhaustive; will be provided in the final report

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/